3582 completed. 3582 Phase 2, 443 Phase 1, 392 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3582 | Completed 3582 |
| Phase 1 | 443 | Completed 443 |
| Phase 3 | 392 | Completed 392 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intranasal Insulin to Prevent Intensive Care Unit Delirium Intranasal insulin-40U, Intranasal sodium chloride 0.9% - Delirium - Postoperative | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 30 | 2026-04-30 | 2026-08-03 |
| Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery Dexmedetomidine (Low dose), Dexmedetomidine (High dose), Fentanyl - Delirium - Postoperative | Phase 2 | Completed | Benha University | 75 | 2026-02-26 | 2026-08-25 |
| Fisetin in Mild Alzheimer's Disease Fisetin - Alzheimer s Disease, Alzheimer Dementia | Phase 2 | Completed | Sunnybrook Health Sciences Centre | 5 | 2026-01-27 | 2026-08-20 |
| PATH to Reducing Burnout Among Peers Who Deliver Overdose Prevention Services (R61 Phase Pilot) PATH (Peer Advanced Training for total Health) - Burnout, Compassion Satisfaction | Phase 2 | Completed | Chestnut Health Systems | 18 | 2026-01-12 | 2026-10-16 |
| Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone Risperidone 4mg/day, Ashwagandha, Placebo - Schizophrenia Patients, Neuroinflammation | Phase 2 | Completed | Hasanuddin University | 80 | 2025-10-01 | 2026-05-12 |
| A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances RE03, Placebo - Posttraumatic Stress Disorder (PTSD), Sleep Disturbances and Insomnia | Phase 2 | Completed | Reconnect Labs | 12 | 2025-09-30 | 2026-07-23 |
| A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder ENX-102, Placebo - Social Anxiety Disorder (SAD) | Phase 2 | Completed | Engrail Therapeutics INC | 47 | 2025-09-05 | 2026-04-08 |
| A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia KYN-5356 low dose, Placebo, KYN-5356 Medium Dose - Cognitive Impairment Associated With Schizophrenia (CIAS) | Phase 2 | Completed | Kynexis B.V. | 149 | 2025-08-27 | 2026-10-23 |
| Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study Risk managment, Dasatinib, Quercetin (dietary supplement) - Aging, Cognitive Decline | Phase 2 | Completed | Washington University School of Medicine | 23 | 2025-07-28 | 2026-08-19 |
| Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients Ropanicant, Placebo - Major Depressive Disorder (MDD) | Phase 2 | Completed | Suven Life Sciences Limited | 214 | 2025-07-15 | 2026-04-07 |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia Placebo, ML-007C-MA BID, ML-007C-MA QD - Schizophrenia | Phase 2 | Completed | MapLight Therapeutics | 307 | 2025-06-27 | 2026-07-09 |
| Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder BXCL501 Sublingual Film - Bipolar I Disorder, Bipolar II Disorder | Phase 2 | Completed | BioXcel Therapeutics Inc | 33 | 2025-06-19 | 2026-10-05 |
| Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder) Esketamine (Intranasal Spray), Massed Prolonged Exposure (PE) - Post Traumatic Stress Disorder PTSD | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 4 | 2025-06-09 | 2026-01-28 |
| Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models Bumetanide, Treatment as usual (TAU) - Autism Spectrum Disorder | Phase 2 | Completed | Fei Li | 66 | 2025-06-04 | 2026-04-29 |
| The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery oxytocin nasal spray - Cervical Spinal Stenosis, Thoracic Spinal Stenosis | Phase 2 | Completed | Zhejiang University | 227 | 2025-06-01 | 2026-08-20 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior Low Dose PRT042 nasal spray, median Dose PRT042 nasal spray, high dose PRT042 nasal spray - Major Depressive Disorder (MDD | Phase 2 | Completed | Sichuan Purity Pharmaceutical Technology Co., Ltd. | 98 | 2025-05-27 | 2026-09-09 |
| RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight Pemvidutide, Placebo - Alcohol Use Disorder (AUD) | Phase 2 | Completed | Altimmune, Inc. | 100 | 2025-05-15 | 2026-07-31 |
| Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder EMP-01, EMP-01 Placebo - Social Anxiety Disorder | Phase 2 | Completed | atai Therapeutics, Inc. | 70 | 2025-05-08 | 2026-07-31 |
| A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease ONO-2020, Placebo - Alzheimer Disease | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 260 | 2025-04-24 | 2026-10-22 |
| Efficacy of Nutritional Supplements on Children With Autism Spectrum Disorder Nutritional supplements, Treatment as usual (TAU) - Autism Spectrum Disorder | Phase 2 | Completed | Fei Li | 88 | 2025-04-01 | 2026-04-23 |
Showing 20 of 3582. Sign in to see all of them.
Alzheimer Disease (414) · Depressive Disorder, Major (326) · Schizophrenia (302) · Depression (284) · Alcoholism (245) · Substance-Related Disorders (211) · Anxiety Disorders (206) · Cognitive Dysfunction (189) · Opioid-Related Disorders (179) · Cocaine-Related Disorders (174) · Stress Disorders, Post-Traumatic (167) · Tobacco Use Disorder (154) · Attention Deficit Disorder with Hyperactivity (128) · Dementia (127) · Sleep Initiation and Maintenance Disorders (118)
Nervous System Diseases (1025) · Chemically-Induced Disorders (978) · Substance-Related Disorders (767) · Neurocognitive Disorders (700) · Behavior (658) · Central Nervous System Diseases (634) · Brain Diseases (632) · Neurodegenerative Diseases (541) · Pathological Conditions, Signs and Symptoms (540) · Mood Disorders (476) · Signs and Symptoms (435) · Dementia (417) · Tauopathies (406) · Neurodevelopmental Disorders (355)
Sugars (76) · Cognitive Behavioral Therapy (74) · Buprenorphine (67) · Naltrexone (59) · Therapeutics (49) · Risperidone (48) · Ketamine (44) · Bupropion (43) · Cannabidiol (40) · Varenicline (39) · Acetylcysteine (36) · Sodium Chloride (36) · Oxytocin (35) · Sertraline (35) · Tobacco Use Cessation Devices (35)
National Institute on Drug Abuse (NIDA) (117) · New York State Psychiatric Institute (101) · Yale University (98) · Medical University of South Carolina (62) · Johns Hopkins University (55) · University of Pennsylvania (54) · Massachusetts General Hospital (46) · GlaxoSmithKline (43) · VA Office of Research and Development (39) · University of California, Los Angeles (36) · Pfizer (35) · Eli Lilly and Company (33) · University of Chicago (33) · National Institute of Mental Health (NIMH) (29) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (28)
United States (2531) · Canada (232) · Germany (171) · France (131) · United Kingdom (130) · Spain (109) · Australia (93) · Poland (80) · Russia (75) · Japan (74) · Netherlands (67) · Italy (62) · Sweden (57) · China (51) · Brazil (46)
Warren Bickel, Ph.D. (17) · Walter Ling, M.D. (15) · Dorothy Hatsukami, Ph.D. (12) · Thomas R Kosten, M.D. (9)
PMID 37811711, PMID 37230961, PMID 37142273, PMID 40342086, PMID 28433500, PMID 34510411, PMID 34582562, PMID 36375174, PMID 31065731, PMID 31572236, PMID 32500209, PMID 36130734, PMID 42560883, PMID 23146246, PMID 25918556, PMID 25938124, PMID 33189083, PMID 33974419, PMID 34532852, PMID 39800465, PMID 25890643, PMID 32628945, PMID 33079196, PMID 33854317, PMID 34091867, PMID 34242666, PMID 34255068, PMID 36006807, PMID 36208817, PMID 36463457, PMID 38236223, PMID 38706271, PMID 12150647, PMID 18632997, PMID 20707781, PMID 20732631, PMID 21156272, PMID 21782353, PMID 22024004, PMID 22170209, PMID 22992330, PMID 23251869, PMID 24001701, PMID 24144615, PMID 24506079, PMID 25175864, PMID 25192771, PMID 25731629, PMID 25988365, PMID 26763495
2009 (18), 2015 (17), 2016 (16), P50DA009236 (13), 2017 (12), 2014 (11), 2018 (9), 2019 (8), 2008 (7), P50DA009262 (7), R01DA008391 (7), 2023 (6), R01DA006969 (6), P50DA009250 (5), P50DA012756 (5)